Literature DB >> 8865529

Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency.

P R Ames1, C Tommasino, L Iannaccone, M Brillante, R Cimino, V Brancaccio.   

Abstract

To explore the coagulation/fibrinolytic balance and its relation with free protein S (f-PS) in subjects with antiphospholipid antibodies (aPLs) outside the setting of autoimmune inflammatory disorders, we carried out a cross-sectional study on 18 thrombotic patients with primary antiphospholipid syndrome and 18 apparently healthy subjects with persistence of idiopathic aPLs. Prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT) and D-Dimer (D-D) were taken as markers of thrombin generation and fibrin turnover. Mean F1 + 2 levels were higher in thrombotic (p = 0.006) and non-thrombotic subjects (p = 0.0001) than in controls as were those of D-D (p < 0.0001 and p = 0.003 respectively). TAT levels did not differ. Lower mean levels of f-PS were found in thrombotic (p = 0.0006) and non-thrombotic subjects (p = 0.002) than in controls. Within both groups, mean F1 + 2 levels were higher in subjects who had low f-PS levels compared to those with normal f-PS levels (p = 0.01). Gender analysed data revealed blunted tPA release (venous occlusion test) in thrombotic females (from 16.80 +/- 0.79 to 21.3 +/- 3.9 ng/nl, NS) but not in thrombotic males (from 18.2 +/- 2.0 to 33.7 +/- 4.9 ng/ml, p=0.01) nor in asymptomatic subjects of either sex. Also, in both patient groups females had higher mean PAI than males (p < 0.0002) and than control females (p < 0.02). Low free protein S was found in 100% of non-thrombotic and in 90% of thrombotic patients with defective fibrinolysis. These data are consistent with increased thrombin generation, accelerated fibrin turnover and fibrinolysis abnormalities also in asymptomatic carriers of aPLs and highlight a central role for acquired f-PS deficiency in the thrombotic tendency of the antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8865529

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Impaired fibrinolysis in the antiphospholipid syndrome.

Authors:  Katie A Krone; Kristi L Allen; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 2.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 3.  The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome.

Authors:  Rohan Willis; E B Gonzalez; A R Brasier
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

4.  Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.

Authors:  T Atsumi; M A Khamashta; O Amengual; S Donohoe; I Mackie; K Ichikawa; T Koike; G R Hughes
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

5.  Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome.

Authors:  N K Singh; A Gupta; Dibya R Behera; D Dash
Journal:  Rheumatol Int       Date:  2013-03-22       Impact factor: 2.631

Review 6.  Pathophysiology of the antiphospholipid antibody syndrome.

Authors:  Rohan Willis; Silvia S Pierangeli
Journal:  Auto Immun Highlights       Date:  2011-03-24

7.  Platelet-activating factor acetylhydrolase in primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Luis L Lopez; Mira Merashli; Eiji Matsuura
Journal:  Auto Immun Highlights       Date:  2018-02-10

Review 8.  Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.

Authors:  Jason S Knight; Yogendra Kanthi
Journal:  Semin Immunopathol       Date:  2022-02-04       Impact factor: 11.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.